GlassScriptPhysician profile
Neil M Brown
NPI 1518965243
$1,443.87
in general payments reported to CMS, 2019-2025
25 companies · $141 in 2025
The $141 reported for 2025 was more than what a typical Neurology (Chiropractor) provider received nationally (typical 2025 total: $122).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $58.29 · 2021: $276 · 2022: $113 · 2023: $212 · 2024: $135 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integrity Implants INC. | $337.67 | 2019 | |
| Collegium Pharmaceutical, INC. | $215.24 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.46 | 2019-2023 | Relistor |
| Genzyme Corporation | $121.93 | 2019-2022 | |
| Abbott Laboratories | $88.28 | 2023-2024 | Immunalysis Corporation, Proclaim |
| Abbvie INC. | $61.41 | 2025 | |
| Argenx US, INC. | $41.51 | 2023 | Vyvgart |
| Csl Behring | $38.99 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $37.87 | 2022 | |
| Medtronic, INC. | $37.21 | 2025 | Inceptiv, Intellis Adaptivestim |
| Catalyst Pharmaceuticals, INC. | $36.59 | 2023 | Firdapse |
| Si-Bone, INC. | $36.36 | 2019 | |
| Nevro Corp. | $29.11 | 2019 | |
| Idorsia Pharmaceuticals US INC | $27.68 | 2023-2024 | Quviviq |
| Amgen INC. | $26.95 | 2025 | Uplizna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $26.90 | 2019-2025 | Vercise |
| Jazz Pharmaceuticals INC. | $20.62 | 2024 | |
| Spr Therapeutics, INC | $18.88 | 2023 | Sprint Pns System |
| Upsher-Smith Laboratories LLC | $18.70 | 2019 | |
| Bausch Health US, LLC | $17.21 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.84 | 2023 | Nuedexta |
| Grifols USA, LLC | $16.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.40 | 2022 | |
| Valinor Pharma, LLC | $14.81 | 2024 | Movantik |
| Masimo Corporation | $13.25 | 2024 | Patient Safetynet System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.